Equities Analysts Offer Predictions for BCYC FY2024 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Research analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a note issued to investors on Monday, January 13th. Leerink Partnrs analyst J. Chang now expects that the company will earn ($3.01) per share for the year, up from their previous forecast of ($3.03). The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Bicycle Therapeutics' Q4 2024 earnings at ($0.83) EPS, Q1 2025 earnings at ($0.84) EPS, Q2 2025 earnings at ($0.86) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.87) EPS and FY2025 earnings at ($3.43) EPS.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04. The company had revenue of $2.68 million during the quarter, compared to analysts' expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics's revenue for the quarter was down 50.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.26) earnings per share.

Several other research analysts also recently issued reports on BCYC. Needham & Company LLC restated a "buy" rating and set a $32.00 price objective on shares of Bicycle Therapeutics in a report on Monday. JMP Securities lowered their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a research note on Wednesday, December 18th. HC Wainwright reiterated a "buy" rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research report on Monday. Stephens assumed coverage on Bicycle Therapeutics in a report on Friday, November 8th. They set an "equal weight" rating and a $25.00 price objective on the stock. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $34.50.

Bicycle Therapeutics Trading Down 6.6 %

NASDAQ:BCYC traded down $0.96 during trading hours on Thursday, hitting $13.59. 288,033 shares of the company traded hands, compared to its average volume of 381,233. Bicycle Therapeutics has a twelve month low of $12.17 and a twelve month high of $28.67. The firm has a 50-day moving average of $17.77 and a 200 day moving average of $21.51. The stock has a market capitalization of $938.39 million, a price-to-earnings ratio of -4.13 and a beta of 0.92.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC bought a new stake in shares of Bicycle Therapeutics during the third quarter worth $3,406,000. The Manufacturers Life Insurance Company grew its holdings in Bicycle Therapeutics by 33.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company's stock worth $2,935,000 after acquiring an additional 32,313 shares during the last quarter. Principal Financial Group Inc. bought a new stake in Bicycle Therapeutics during the 3rd quarter worth about $10,028,000. State Street Corp increased its position in Bicycle Therapeutics by 233.5% in the 3rd quarter. State Street Corp now owns 86,271 shares of the company's stock valued at $1,952,000 after acquiring an additional 60,399 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new position in shares of Bicycle Therapeutics during the second quarter worth approximately $11,577,000. 86.15% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the sale, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 985,397 shares of the business's stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the acquisition, the director now directly owns 9,537,643 shares in the company, valued at $131,237,967.68. The trade was a 11.52 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 33,933 shares of company stock worth $549,501 in the last 90 days. 8.50% of the stock is owned by company insiders.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.